TL;DR: A 2025 meta-analysis published in The Laryngoscope analysed 20 studies (1,687 patients) and found that hyperbaric oxygen therapy (HBOT) combined with medical therapy more than doubles the odds of hearing recovery in sudden sensorineural hearing loss (SSNHL). These findings reinforce HBOT as a UHMS-approved adjunct to corticosteroids, with treatment initiation within 14 days of onset being critical for optimal outcomes.

Sudden sensorineural hearing loss (SSNHL) is a medical emergency defined as a rapid loss of hearing, typically in one ear, occurring over 72 hours or less. Estimated reading time: 5 minutes

What Does the Latest Evidence Say About HBOT for Sudden Hearing Loss?

Hyperbaric oxygen therapy for sudden hearing loss is supported by growing clinical evidence. A comprehensive 2025 systematic review and meta-analysis published in The Laryngoscope by Alter et al. examined 20 studies – including 16 randomised controlled trials – involving 1,087 patients who received HBOT and 600 who received standard medical therapy alone (DOI: 10.1002/lary.32472).

Sudden sensorineural hearing loss (SSNHL) is a rapid-onset hearing deficit of at least 30 dB across three consecutive frequencies within 72 hours. It is a medical emergency requiring prompt intervention. The Undersea and Hyperbaric Medical Society (UHMS) recognises HBOT as an approved indication for this condition, and Health Canada-approved hyperbaric chambers are used to deliver treatment at accredited facilities across the country.

What Were the Key Findings of This Meta-Analysis?

The pooled analysis revealed that patients receiving HBOT in combination with medical therapy had 2.61 times higher odds of hearing recovery compared to those treated with medical therapy alone (95% CI 1.86–3.68, p < 0.001). Two important subgroup analyses confirmed the benefit:

  • HBOT + systemic steroids vs. systemic steroids alone: OR 2.54 (95% CI 1.63–3.97, p < 0.001)
  • HBOT + systemic steroids + intratympanic steroids vs. systemic + intratympanic steroids alone: OR 2.64 (95% CI 1.39–5.02, p < 0.001)

These results align with a concurrent meta-analysis by Newth et al. in Diving and Hyperbaric Medicine, which reported a relative risk of 1.6 (95% CI 1.3–2.0) and a mean improvement of 15.6 dB with HBOT (DOI: 10.28920/dhm55.4.398-406). That review characterised the evidence as moderate quality and concluded HBOT can be “justified as a routine treatment” alongside steroids.

How Does Hyperbaric Oxygen Therapy Work in SSNHL?

Hyperbaric oxygen therapy is a treatment in which a patient breathes 100% oxygen at pressures greater than sea level inside a pressurised chamber. In SSNHL, the proposed mechanism involves:

  1. Increasing oxygen delivery to the cochlea, which depends on oxygen diffusion from perilymph
  2. Reducing oedema in the inner ear structures
  3. Enhancing microvascular blood flow to the stria vascularis
  4. Modulating inflammatory cascades that contribute to cochlear damage

The cochlea is particularly vulnerable to oxygen deprivation because it lacks direct vascular supply to the organ of Corti. HBOT significantly increases perilymph oxygen tension, which may restore function in damaged but viable hair cells.

Why Early Treatment Matters: The 14-Day Window

Timing is the single most important variable in HBOT outcomes for sudden sensorineural hearing loss. The cochlea’s hair cells – responsible for converting sound vibrations into nerve signals – are highly sensitive to oxygen deprivation. Once these cells die, they do not regenerate. HBOT’s ability to restore hearing therefore depends on intervening while damaged but still-viable cells remain salvageable.

The Biological Mechanism Behind the Time Limit

When SSNHL occurs, blood flow to the cochlea is disrupted, triggering a cascade of injury. Ischaemia causes intracellular oedema in the stria vascularis and the organ of Corti. Inflammatory mediators accumulate in the perilymph, further damaging hair cells. Within hours to days, this microenvironment shifts from one of injury to one of irreversible degeneration.

Hyperbaric oxygen therapy interrupts this cascade through two primary mechanisms:

  • Hyperoxic augmentation of perilymph oxygen tension: At 2.0–2.4 ATA breathing 100% oxygen, dissolved oxygen in plasma rises approximately 10- to 15-fold above normal levels. This dramatically increases perilymph oxygen tension – the inner ear’s functional oxygen supply – even in the absence of adequate blood flow through cochlear vessels.
  • Anti-inflammatory and anti-oedematous effects: Elevated oxygen tension modulates reactive oxygen species signalling, downregulates pro-inflammatory cytokines, and reduces endolymphatic hydrops (fluid swelling within the cochlea). This combination reduces further cellular damage and creates conditions under which partial or full hair cell recovery may occur.

The 14-day window reflects the period during which a meaningful proportion of hair cells remain injured but alive. Multiple studies have confirmed that HBOT initiated within this window produces significantly better outcomes than treatment started later. After approximately 30 days, the probability of meaningful recovery with HBOT diminishes substantially, as irreversible degeneration becomes the predominant pathological state.

For patients and referring physicians, this means that SSNHL should be treated as a time-sensitive emergency, comparable to a stroke. Any patient presenting with unexplained rapid hearing loss should be assessed by an otolaryngologist promptly, and HBOT referral should be considered in parallel with steroid therapy – not after steroid failure alone.

What to Expect During HBOT for Hearing Loss

For patients unfamiliar with hyperbaric medicine, the treatment environment can seem unfamiliar. Understanding what actually happens during a session helps reduce anxiety and supports treatment completion – which is important, as consistent attendance throughout the full prescribed course is associated with better outcomes.

Before Your First Session

You will attend a pre-treatment assessment at the hyperbaric facility. A hyperbaric physician will review your audiogram, medical history, and current medications. You will undergo a physical examination and chest X-ray to confirm the absence of contraindications. The team will explain ear-clearing techniques (such as the Valsalva manoeuvre) that you will use during pressurisation to equalise middle ear pressure.

During a Typical Session

Sessions take place in a pressurised chamber – either a monoplace chamber (single-person, clear acrylic) or a multiplace chamber (multiple patients seated together). Each session lasts approximately 90 minutes. The sequence is:

  • Compression (10–15 minutes): Chamber pressure rises gradually from 1.0 to 2.0–2.4 ATA. You will feel pressure in your ears and will use the Valsalva manoeuvre to equalise, much like descending in an aeroplane.
  • Treatment phase (60–75 minutes): You breathe 100% oxygen continuously through a mask or hood while the chamber remains at treatment pressure. Many patients read, watch a film, or rest during this time.
  • Decompression (10–15 minutes): Pressure returns gradually to normal. You may notice slight ear popping as pressure equalises on ascent.

How Many Sessions Will You Need?

Standard protocols for SSNHL involve 10 to 20 sessions, typically scheduled once daily, Monday through Friday. Your hyperbaric physician will conduct repeat audiometric testing during your course to monitor your response. If your hearing is improving, the full course is completed. If there is no measurable improvement after the initial sessions, the team will reassess and discuss options with you.

Common Experiences During Treatment

Most patients tolerate HBOT well. The most commonly reported experience is mild ear pressure during compression, which resolves with proper equalisation technique. Some patients feel slightly tired after early sessions as the body adjusts. Temporary changes in vision (mild myopia) can occur with extended courses but typically resolve within weeks of completing treatment. Serious adverse events are rare at accredited facilities with trained staff.

What Are the Clinical Implications for Referring Physicians in Canada?

For Canadian physicians managing SSNHL, this evidence supports early referral for HBOT as an adjunct to corticosteroid therapy. Key clinical considerations include:

  • Timing is critical: HBOT should ideally begin within 14 days of symptom onset, with some evidence suggesting benefit up to 30 days
  • Treatment protocol: Standard protocols involve 10–20 sessions at 2.0–2.4 ATA for 90 minutes per session
  • Patient selection: SSNHL is a UHMS-approved indication – patients who fail initial steroid therapy are strong candidates for salvage HBOT
  • Coverage: In Ontario, OHIP covers HBOT for approved indications including SSNHL at hospital and eligible private clinics. Coverage varies by province

A separate 2025 meta-analysis by Moghib et al. in the European Archives of Oto-Rhino-Laryngology further confirmed that HBOT significantly improved low-frequency hearing thresholds (SMD: 0.83, p < 0.0001) and doubled the odds of complete recovery (OR: 2.05, p = 0.0002) across 14 RCTs with 794 participants (DOI: 10.1007/s00405-025-09372-2).

The Canada Hyperbarics research database catalogues additional studies on HBOT for hearing loss and other approved indications.

What Are the Limitations of This Research?

Significant heterogeneity remains across studies. Variations in treatment protocols (pressure levels, number of sessions, timing of initiation), outcome measures, and definitions of “hearing recovery” make direct comparisons challenging. The Moghib et al. meta-analysis noted an I² value of 96.7%, indicating substantial variation between studies.

A 2025 WHO-affiliated review of clinical practice guidelines identified only three high-quality guidelines worldwide addressing SSNHL management (DOI: 10.1080/14992027.2025.2571797). This underscores the need for standardised international protocols and highlights an opportunity for Canadian hyperbaric medicine to contribute to emerging global standards.

Adverse events – primarily mild barotrauma, ear pressure, and transient vertigo – were reported infrequently and were generally self-limiting.

Frequently Asked Questions

Is HBOT a first-line treatment for sudden hearing loss?

No. Systemic corticosteroids remain the first-line treatment for SSNHL. HBOT is recommended as an adjunctive therapy alongside steroids, or as salvage therapy for cases refractory to initial steroid treatment.

How soon after symptom onset should HBOT begin?

Evidence suggests the sooner the better. Ideally within 14 days, with some benefit observed up to 30 days post-onset. Delayed treatment beyond this window shows diminishing returns.

How many HBOT sessions are typically required for SSNHL?

Standard protocols involve 10 to 20 sessions, with each session lasting approximately 90 minutes at 2.0–2.4 atmospheres absolute (ATA). The exact number depends on the patient’s audiometric response.

Is HBOT for sudden hearing loss covered in Canada?

Coverage varies by province. In Ontario, OHIP covers HBOT for UHMS-approved indications including SSNHL at eligible facilities. In other provinces, coverage may differ – consult the Canada Hyperbarics FAQ for province-specific information.

What are the contraindications for HBOT in SSNHL patients?

Absolute contraindications include untreated pneumothorax. Relative contraindications include upper respiratory infections, uncontrolled seizure disorders, and certain concurrent medications. All patients should be appropriately screened before initiating treatment.

Are there risks or side effects of HBOT?

Adverse events are generally mild and include middle ear barotrauma, temporary myopia, and transient vertigo. Serious complications are rare when treatment is administered at an accredited hyperbaric facility.

Can I receive HBOT for hearing loss if steroids did not help?

Yes. HBOT is particularly valuable as salvage therapy for patients whose hearing did not recover with initial corticosteroid treatment. Clinical guidelines and the UHMS support the use of HBOT in steroid-refractory SSNHL, provided treatment is initiated within the therapeutic time window. Discuss this option with your otolaryngologist promptly if you have not responded to steroids.

What happens during a hyperbaric session for hearing loss?

You will enter a pressurised chamber – either alone (monoplace) or with other patients (multiplace) – and breathe 100% oxygen through a mask or hood for approximately 90 minutes. The session begins with a gradual compression phase, during which you will clear your ears using the Valsalva manoeuvre, followed by the treatment phase at 2.0–2.4 ATA, and then a gentle decompression back to normal pressure. Most patients find the experience comfortable and tolerate the full course without significant difficulty.

Does HBOT restore full hearing, or only partial improvement?

Outcomes vary depending on the severity of the initial hearing loss, the frequency range affected, how quickly treatment was started, and individual patient factors. The 2025 meta-analysis found that HBOT more than doubled the odds of recovery, with an average improvement of 15.6 dB across studies. Some patients recover fully; others experience partial improvement. Even partial recovery can be clinically meaningful – for example, restoring speech-frequency hearing sufficient for unaided conversation.

Conclusion and Referral Pathway

The 2025 evidence strongly supports HBOT as a valuable adjunct to corticosteroid therapy for SSNHL. Referring physicians in Canada should consider early referral to an accredited hyperbaric facility for patients presenting with sudden hearing loss, particularly when initial steroid therapy has not achieved adequate recovery. Time-sensitive referral remains the most important factor in optimising patient outcomes.

For a complete directory of accredited hyperbaric facilities across Canada, visit the Canada Hyperbarics clinic directory.

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for clinical decisions regarding patient care.